Tisotumab vedotin + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer: phase 1b/2 ENGOT-Cx8/GOG-3024/innovaTV 205 study dose-escalation results
Monk, BJ; Van Gorp, T; Lorusso, Det al.
2021 • 2021 IGCS Annual Global Meeting; August 30-September 2, 2021; virtual. Plenary 5
Tisotumab vedotin + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer: phase 1b/2 ENGOT-Cx8/GOG-3024/innovaTV 205 study dose-escalation results
Publication date :
30 August 2021
Event name :
2021 IGCS Annual Global Meeting; August 30-September 2, 2021; virtual. Plenary 5